Design Therapeutics (DSGN) Payables (2020 - 2026)

Design Therapeutics has reported Payables for 7 years, with the latest figure at $3.1 million in Q2 2026.

• Payables for Q2 2026 came in at $3.1 million, up 210.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.1 million (up 210.07% YoY), and the FY2025 annual result was $2.3 million, up 5.76% from the prior year.
• Payables rose to $3.1 million in Q2 2026, from $2.3 million in the prior quarter.
• Over five years, Payables peaked at $3.2 million in Q1 2025 and troughed at $1.0 million in Q2 2025.
• A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Payables.
• The widest annual swing landed in 2024, when Payables plunged 50.0%; it then jumped 210.07% in 2026.
• A 5-year view of Payables shows it stood at $3.0 million in 2022, then slumped by 35.87% to $1.9 million in 2023, then gained by 12.68% to $2.2 million in 2024, then gained by 5.76% to $2.3 million in 2025, then jumped by 35.86% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $3.1 million in Q2 2026, $2.3 million in Q1 2026, and $2.3 million in Q4 2025.